The use of electroporation to deliver DNA-based vaccines

References

• Elizaga ML, Li SS, Kochar NK, et al. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS One. 2018;13(9):e0202753. doi: 10.1371/journal.pone.0202753
   PubMed Web of Science ®Google Scholar
• Houser KV, Chen GL, Carter C, et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med. 2022;28(2):383–391. doi: 10.1038/s41591-021-01660-8
   PubMed Web of Science ®Google Scholar
• Hooper J, Paolino KM, Mills K, et al. A phase 2a randomized, double-blind, dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Vaccines (Basel). 2020;8(3):1–21. doi: 10.3390/vaccines8030377
   Web of Science ®Google Scholar
• Hannaman D, Dupuy LC, Ellefsen B, et al. A phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation. Vaccine. 2016;34(31):3607–3612. doi: 10.1016/j.vaccine.2016.04.077
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Houser KV, Morabito KM, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018;391(10120):552–562. doi: 10.1016/S0140-6736(17)33105-7
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Pierson TC, Hubka SA, et al. A west Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396–1404. doi: 10.1093/infdis/jir054
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding ebolavirus and marburgvirus wild-type glycoproteins in a phase i clinical trial. J Infect Dis. 2015;211(4):549–557. doi: 10.1093/infdis/jiu511
   PubMed Web of Science ®Google Scholar
• Tebas P, Kraynyak KA, Patel A, et al. Intradermal SynCon® Ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. J Infect Dis. 2019;220(3):400–410. doi: 10.1093/infdis/jiz132
   PubMed Web of Science ®Google Scholar
• Ahn JY, Lee J, Suh YS, et al. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe. 2022;3(3):e173–e183. doi: 10.1016/S2666-5247(21)00358-X
   PubMedGoogle Scholar
• Kraynyak KA, Blackwood E, Agnes J, et al. SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial. J Infect Dis. 2022;225(11):1923–1932. doi: 10.1093/infdis/jiac016
   PubMed Web of Science ®Google Scholar
• Jenkins M, Kerr D, Fayer R, et al. Serum and colostrum antibody responses induced by jet-injection of sheep with DNA encoding a Cryptosporidium parvum antigen. Vaccine. 1995;13(17):1658–1664. doi: 10.1016/0264-410X(95)00121-G
   PubMed Web of Science ®Google Scholar
• Gül C, Karakavuk T, Karakavuk M, et al. An overview of DNA vaccines development studies against Toxoplasma gondii. Turkiye Parazitoloji Dergisi. 2022;46:253–270. doi: 10.4274/tpd.galenos.2022.02486
   PubMedGoogle Scholar
• Sefidi-Heris Y, Jahangiri A, Mokhtarzadeh A, et al. Recent progress in the design of DNA vaccines against tuberculosis. Drug Discov Today. 2020;25(11):1971–1987. doi: 10.1016/j.drudis.2020.09.005
   Web of Science ®Google Scholar
• Lee J, Arun Kumar S, Jhan YY, et al. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;80:31–47. doi: 10.1016/j.actbio.2018.08.033
   PubMed Web of Science ®Google Scholar
• Carter EW, Kerr DE. Optimization of DNA-based vaccination in cows using green fluorescent protein and protein a as a prelude to immunization against staphylococcal mastitis. J Dairy Sci. 2003;86(4):1177–1186. doi: 10.3168/jds.S0022-0302(03)73701-1
   PubMed Web of Science ®Google Scholar
• Scheiblhofer S, Weiss R, Thalhamer J. Genetic vaccination approaches against malaria based on the circumsporozoite protein. Wiener Klinische Wochenschrift, Supplement. 2006;118(S3):9–17. doi: 10.1007/s00508-006-0676-0
   Google Scholar
• Cai Y, Rodriguez S, Hebel H. DNA vaccine manufacture: Scale and quality. Expert Rev Vaccines. 2009;8(9):1277–1291. doi: 10.1586/erv.09.84
   PubMed Web of Science ®Google Scholar
• Shafaati M, Saidijam M, Soleimani M, et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 2022;17(1):49–66. doi: 10.2217/fvl-2021-0170
   Web of Science ®Google Scholar
• Li L, Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15(3):313–329. doi: 10.1586/14760584.2016.1124762
   PubMed Web of Science ®Google Scholar
• Bazhan SI, Antonets DV, Starostina EV, et al. In silico design of influenza a virus artificial epitope-based T-cell antigens and the evaluation of their immunogenicity in mice. J Biomol Struct Dyn. 2022;40(7):3196–3212. doi: 10.1080/07391102.2020.1845978
   PubMed Web of Science ®Google Scholar
• Bazhan SI, Antonets DV, Karpenko LI, et al. In silico designed Ebola virus T-cell multi-epitope DNA vaccine constructions are immunogenic in mice. Vaccines (Basel). 2019;7.
   PubMed Web of Science ®Google Scholar
• Karpenko LI, Bazhan SI, Eroshkin AM, et al. Artificial epitope-based immunogens in HIV-vaccine design. In: Adv HIV AIDS Control. IntechOpen; 2018. p. 205–225. doi: 10.5772/intechopen.77031
   Google Scholar
• Liu L. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019;7(2):37. doi: 10.3390/vaccines7020037
   PubMed Web of Science ®Google Scholar
• Braathen R, Spång HCL, Hinke DM, et al. A DNA vaccine that encodes an antigen-presenting cell-specific heterodimeric protein protects against cancer and influenza. Mol Ther Methods Clin Dev. 2020;17:378–392. doi: 10.1016/j.omtm.2020.01.007
   PubMed Web of Science ®Google Scholar
• Kim D, Wu Y, Kim YB, et al. Advances in vaccine delivery systems against viral infectious diseases. Drug Deliv Transl Res. 2021;11(4):1401–1419. doi: 10.1007/s13346-021-00945-2
   PubMed Web of Science ®Google Scholar
• Karpenko LI, Apartsin EK, Dudko SG, et al. Cationic polymers for the delivery of the Ebola DNA vaccine encoding artificial t-cell immunogen. Vaccines (Basel). 2020;8(4):8. doi: 10.3390/vaccines8040718
   Web of Science ®Google Scholar
• Franck CO, Fanslau L, Bistrovic Popov A, et al. Biopolymer-based carriers for DNA vaccine design. Angew Chem Int Ed. 2021;133(24):13333–13351. doi: 10.1002/ange.202010282
   Google Scholar
• Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Hum Vaccin Immunother. 2017;13(12):2837–2848. doi: 10.1080/21645515.2017.1330236
   PubMed Web of Science ®Google Scholar
• Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol. 2020;65:21–27. doi: 10.1016/j.coi.2020.01.006
   PubMed Web of Science ®Google Scholar
• Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines: Sixth Edition; 2013. p. 1200–1231.
   Google Scholar
• Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov. 2006;5(7):543–548. doi: 10.1038/nrd2076
   PubMed Web of Science ®Google Scholar
• Wang R, Bian Q, Xu Y, et al. Recent advances in mechanical force-assisted transdermal delivery of macromolecular drugs. Int J Pharm. 2021;602:602. doi: 10.1016/j.ijpharm.2021.120598
   Google Scholar
• Momin T, Kansagra K, Patel H, et al. Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClin Med. 2021;38:101020. doi: 10.1016/j.eclinm.2021.101020
   PubMedGoogle Scholar
• Mallapaty S. India’s DNA COVID vaccine is a world first – more are coming. Nature. 2021;597(7875):161–162. doi: 10.1038/d41586-021-02385-x
   PubMed Web of Science ®Google Scholar
• Petkov SP, Heuts F, Krotova OA, et al. Evaluation of immunogen delivery by DNA immunization using non-invasive bioluminescence imaging. Hum Vaccin Immunother. 2013;9(10):2228–2236. doi: 10.4161/hv.25561
   PubMed Web of Science ®Google Scholar
• Eusébio D, Neves AR, Costa D, et al. Methods to improve the immunogenicity of plasmid DNA vaccines. Drug Discov Today. 2021;26(11):2575–2592. doi: 10.1016/j.drudis.2021.06.008
   PubMed Web of Science ®Google Scholar
• Saljoughian N, Zahedifard F, Doroud D, et al. Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunol. 2013;35(12):397–408. doi: 10.1111/pim.12042
   PubMed Web of Science ®Google Scholar
• Coster HGL. A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of “punch-through”. Biophys J. 1965;5(5):669–686. doi: 10.1016/S0006-3495(65)86745-5
   PubMed Web of Science ®Google Scholar
• Coster HGL, George EP, Simons R. The electrical characteristics of fixed charge membranes. Biophys J. 1969;9(5):666–684. doi: 10.1016/S0006-3495(69)86411-8
   PubMed Web of Science ®Google Scholar
• Sale AJH, Hamilton WA. Effects of high electric fields on micro-organisms. III. Lysis of erythrocytes and protoplasts. BBA - Biomembr. 1968;163(1):37–43. doi: 10.1016/0005-2736(68)90030-8
   PubMedGoogle Scholar
• Neumann E, Schaefer-Ridder M, Wang Y, et al. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1982;1(7):841–845. doi: 10.1002/j.1460-2075.1982.tb01257.x
   PubMed Web of Science ®Google Scholar
• Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther. 1993;4(2):151–159. doi: 10.1089/hum.1993.4.2-151
   PubMed Web of Science ®Google Scholar
• Neumann E, Kakorin S, Tœnsing K. Fundamentals of electroporative delivery of drugs and genes. Bioelectrochem Bioenerg. 1999;48(1):3–16. doi: 10.1016/S0302-4598(99)00008-2
   PubMed Web of Science ®Google Scholar
• McMahon JM, Signori E, Wells KE, et al. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase – increased expression with reduced muscle damage. Gene Ther. 2001;8(16):1264–1270. doi: 10.1038/sj.gt.3301522
   PubMed Web of Science ®Google Scholar
• Mennuni C, Calvaruso F, Zampaglione I, et al. Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum Gene Ther. 2002;13(3):355–365. doi: 10.1089/10430340252792495
   PubMed Web of Science ®Google Scholar
• Vilquin JT, Kennel PF, Paturneau-Jouas M, et al. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. 2001;8(14):1097–1107. doi: 10.1038/sj.gt.3301484
   PubMed Web of Science ®Google Scholar
• Gollins H, McMahon J, Wells KE, et al. High-efficiency plasmid gene transfer into dystrophic muscle. Gene Ther. 2003;10(6):504–512. doi: 10.1038/sj.gt.3301927
   PubMed Web of Science ®Google Scholar
• Vicat JM, Boisseau S, Jourdes P, et al. Brief report: muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression. Hum Gene Ther. 2000;11(6):909–916. doi: 10.1089/10430340050015518
   PubMed Web of Science ®Google Scholar
• Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421–429. . doi: 10.1016/j.coi.2011.03.008
   PubMed Web of Science ®Google Scholar
• Cukjati D, Batiuskaite D, André F, et al. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry. 2007;70(2):501–507. doi: 10.1016/j.bioelechem.2006.11.001
   PubMed Web of Science ®Google Scholar
• Trollet C, Bloquel C, Scherman D, et al. Electrotransfer into Skeletal Muscle for Protein Expression. Curr Gene Ther. 2006;6. doi: 10.1186/1472-6750-6-16
   Web of Science ®Google Scholar
• Becker SM, Kuznetsov AV. Local temperature rises influence in vivo electroporation pore development: A numerical stratum corneum lipid phase transition model. J Biomech Eng. 2007;129(5):712–721. doi: 10.1115/1.2768380
   PubMed Web of Science ®Google Scholar
• Daugimont L, Baron N, Vandermeulen G, et al. Hollow microneedle arrays for intradermal drug delivery and DNA electroporation. J Membr Biol. 2010;236(1):117–125. doi: 10.1007/s00232-010-9283-0
   PubMed Web of Science ®Google Scholar
• Gothelf A, Gehl J. What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother. 2012;8(11):1694–1702. doi: 10.4161/hv.22062
   PubMed Web of Science ®Google Scholar
• Adam L, Tchitchek N, Todorova B, et al. Innate molecular and cellular signature in the skin preceding long-lasting T cell responses after electroporated DNA vaccination. J Immunol. 2020;204(12):3375–3388. doi: 10.4049/jimmunol.1900517
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Nold MF, Zepp JA, et al. IL-32–dependent effects of IL-1β on endothelial cell functions. Proc Natl Acad Sci U S A Internet. 2009 [cited 2023 Oct 6];106(10):3883. 10.1073/pnas.0813334106
   PubMed Web of Science ®Google Scholar
• Dolgachev V, Panicker S, Balijepalli S, et al. Electroporation-mediated delivery of FER gene enhances innate immune response and improves survival in a murine model of pneumonia. Gene Ther. 2018;25(5):359–375. doi: 10.1038/s41434-018-0022-y
   PubMed Web of Science ®Google Scholar
• Arnold CE, Rajnicek AM, Hoare JI, et al. Physiological strength electric fields modulate human T cell activation and polarisation. Sci Rep. 2019;9(1). doi: 10.1038/s41598-019-53898-5
   Google Scholar
• Chiarella P, Massi E, De Robertis M, et al. Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration. Expert Opin Biol Ther. 2008;8(11):1645–1657. doi: 10.1517/14712598.8.11.1645
   PubMed Web of Science ®Google Scholar
• Tebas P, Yang SP, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:31. doi: 10.1016/j.eclinm.2020.100689
   Google Scholar
• Polajzer T, Jarm T, Miklavcic D. Analysis of damage-associated molecular pattern molecules due to electroporation of cells in vitro. Radiol Oncol. 2020;54(3):317–328. doi: 10.2478/raon-2020-0047
   PubMed Web of Science ®Google Scholar
• Schultheis K, Smith TRF, Kiosses WB, et al. Delineating the cellular mechanisms associated with skin electroporation. Hum Gene Ther Methods. 2018;29(4):177–188. doi: 10.1089/hgtb.2017.105
   PubMed Web of Science ®Google Scholar
• Emming S, Bianchi N, Polletti S, et al. A molecular network regulating the proinflammatory phenotype of human memory T lymphocytes. Nat Immunol. 2020;21(4):388–399. doi: 10.1038/s41590-020-0622-8
   PubMed Web of Science ®Google Scholar
• Peletta A, Prompetchara E, Tharakhet K, et al. DNA vaccine administered by cationic lipoplexes or by in vivo electroporation induces comparable antibody responses against sars-cov-2 in mice. Vaccines (Basel). 2021;9(8):874. doi: 10.3390/vaccines9080874
   PubMed Web of Science ®Google Scholar
• Rakoczy K, Kisielewska M, Sędzik M, et al. Electroporation in clinical applications—the potential of Gene Electrotransfer and Electrochemotherapy. Appl Sci (Switzerland). 2022;12(21):10821. doi: 10.3390/app122110821
   Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209. doi: 10.1586/erv.11.188
   PubMed Web of Science ®Google Scholar
• Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–1022. doi: 10.1016/S1473-3099(19)30266-X
   PubMed Web of Science ®Google Scholar
• Andrade VM, Christensen-Quick A, Agnes J, et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. NPJ Vaccin. 2021;6(1):6. doi: 10.1038/s41541-021-00384-7
   PubMed Web of Science ®Google Scholar
• Krotova O, Starodubova E, Petkov S, et al. Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. PLoS One. 2013;8(5):e62720. doi: 10.1371/journal.pone.0062720
   PubMed Web of Science ®Google Scholar
• Latanova AA, Petkov S, Kilpelainen A, et al. Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-Type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity. Sci Rep. 2018;8(1). doi: 10.1038/s41598-018-26281-z
   PubMedGoogle Scholar
• Leroy LA, Mac DA, Kandlur A, et al. Cytokine adjuvants IL-7 and IL-15 improve humoral responses of a SHIV LentiDNA vaccine in animal models. Vaccines (Basel). 2022;10(3):10. doi: 10.3390/vaccines10030461
   Web of Science ®Google Scholar
• Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11: doi: 10.3389/fimmu.2020.583077
   PubMed Web of Science ®Google Scholar
• Sokołowska E, Błachnio-Zabielska AU. A critical review of electroporation as a plasmid delivery system in mouse skeletal muscle. Int J Mol Sci. 2019;20(11):2776. doi: 10.3390/ijms20112776
   PubMed Web of Science ®Google Scholar
• VGX-3100 and electroporation in treating Patients with HIV-Positive high-grade anal lesions | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT03603808?tab=table.
   Google Scholar
• Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT04336410?tab=table.
   Google Scholar
• A study to evaluate Safety & immunogenicity of SARS-CoV-2 DNA vaccine delivered intramuscularly followed by electroporation for COVID-19 | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT05102643?tab=table.
   Google Scholar
• A first-in-human study to evaluate Safety, tolerability, reactogenicity, and immunogenicity of JNJ-64300535, a DNA vaccine, administered by electroporation-mediated intramuscular injection, in participants with chronic hepatitis B who are on stable Nucleos(t)Ide therapy and virologically suppressed | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT03463369?tab=table.
   Google Scholar
• Study of PENNVAXTM-B (gag, Pol, Env) + electroporation in HIV-1 infected Adult participants | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6].
   Google Scholar
• Safety, tolerability and immunogenicity of INO-4800 followed by electroporation in healthy volunteers for COVID19 | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT04447781?tab=table.
   Google Scholar
• Safety and immunogenicity of HIV DNA-C CN54ENV and recombinant HIV CN54gp140 vaccines in healthy volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT02589795?tab=table.
   Google Scholar
• GLS-5700 in Healthy Volunteers | ClinicalTrials.gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02809443.
   Google Scholar
• Dose-finding, Safety study of plasmid DNA Therapeutic vaccine to treat cervical intraepithelial neoplasia | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02139267.
   Google Scholar
• The Safety and immunogenicity of the DNA-GTU vaccine administered to HIV-infected Patients on ART vs placebo | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT02457689?tab=table.
   Google Scholar
• Study of a DNA-based Venezuelan equine encephalitis virus DNA vaccine administered by electroporation in healthy volunteers | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01984983?tab=table.
   Google Scholar
• A phase II trial to assess the Safety and immunogenicity of DNA priming administered by the ID Zetajet® with or without ID derma VaxTM electroporation followed by IM MVA boosting in healthy volunteers in Tanzania and Mozambique | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01697007?tab=table.
   Google Scholar
• Evaluating the Safety of and immune response to an HIV vaccine followed by booster, administered by two devices, in HIV-Uninfected adults | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01260727.
   Google Scholar
• A study of DNA vaccine with electroporation for the prevention of disease caused by H1 and H5 influenza virus | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT01405885?tab=table.
   Google Scholar
• Study of PENNVAXTM-B (gag, Pol, Env) + electroporation in HIV-1 infected Adult participants | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01082692?tab=table.
   Google Scholar
• Study of VGX-3400X, H5N1 avian influenza virus DNA plasmid + electroporation in healthy adults | ClinicalTrials.Gov [Internet]. [cited 2023 Nov 15]. Available from: https://clinicaltrials.gov/study/NCT01142362.
   Google Scholar
• Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268–272. doi: 10.1038/s41586-021-03681-2
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccin Immunol. 2006;13(11):1267–1277. doi: 10.1128/CVI.00162-06
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1595–1606. doi: 10.1016/S0140-6736(20)32137-1
   PubMed Web of Science ®Google Scholar
• Haidari G, Day S, Wood M, et al. The Safety and immunogenicity of GTU®MultiHIV DNA vaccine delivered by Transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART. Front Immunol. 2019;10:10. doi: 10.3389/fimmu.2019.02911
   PubMed Web of Science ®Google Scholar
• Therapeutic vaccination in treated HIV disease | ClinicalTrials.Gov [Internet]. [cited 2023 Oct 6]. Available from: https://clinicaltrials.gov/study/NCT03606213?a=12.
   Google Scholar
• Hettinga J, Carlisle R. Vaccination into the dermal compartment: Techniques, challenges, and prospects. Vaccines (Basel). 2020;8(3):534. doi: 10.3390/vaccines8030534
   PubMed Web of Science ®Google Scholar
• Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PLoS One. 2009;4(9):4. doi: 10.1371/journal.pone.0007226
   Web of Science ®Google Scholar
• Kisakov DN, Kisakova LA, Borgoyakova MB, et al. Optimization of in vivo electroporation conditions and delivery of DNA vaccine encoding SARS-CoV-2 RBD using the determined protocol. Pharmaceutics. 2022;14(11):14. doi: 10.3390/pharmaceutics14112259
   Web of Science ®Google Scholar
• Fusco R, Di Bernardo E, D’Alessio V, et al. Reduction of muscle contraction and pain in electroporation-based treatments: an overview. World J Clin Oncol. 2021;12(5):367–381. doi: 10.5306/wjco.v12.i5.367
   PubMed Web of Science ®Google Scholar
• Petkov S, Kilpeläinen A, Bayurova E, et al. HIV-1 protease as DNA immunogen against Drug resistance in HIV-1 infection: DNA Immunization with Drug resistant HIV-1 protease protects mice from challenge with protease-expressing cells. Cancers (Basel). 2022;15(1):15. doi: 10.3390/cancers15010238
   PubMed Web of Science ®Google Scholar
• Lambert L, Kinnear E, McDonald JU, et al. DNA vaccines encoding antigen targeted to MHC class II induce influenza-specific CD8+ T cell responses, enabling faster resolution of influenza disease. Front Immunol. 2016;7: doi: 10.3389/fimmu.2016.00321
   PubMed Web of Science ®Google Scholar
• Chen J, Huang B, Deng Y, et al. Synergistic immunity and protection in mice by co-immunization with DNA vaccines encoding the spike protein and other structural proteins of SARS-CoV-2. Vaccines (Basel). 2023;11(2):11. doi: 10.3390/vaccines11020243
   Web of Science ®Google Scholar
• Guan J, Deng Y, Chen H, et al. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice. Arch Virol. 2015;160(10):2517–2524. doi: 10.1007/s00705-015-2535-7
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hearn J, Wang E, et al. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis. 2014;209(12):1882–1890. doi: 10.1093/infdis/jiu114
   PubMed Web of Science ®Google Scholar
• Chai KM, Tzeng TT, Shen KY, et al. DNA vaccination induced protective immunity against sars cov-2 infection in hamsterss. PLoS Negl Trop Dis. 2021;15(5):15. doi: 10.1371/journal.pntd.0009374
   Web of Science ®Google Scholar
• Dormeshkin D, Katsin M, Stegantseva M, et al. Design and immunogenicity of SARS-CoV-2 DNA vaccine encoding RBD-PVXCP fusion protein. Vaccines (Basel). 2023;11(6):11. doi: 10.3390/vaccines11061014
   Web of Science ®Google Scholar
• Choi H, Kudchodkar SB, Reuschel EL, et al. Protective immunity by an engineered DNA vaccine for Mayaro virus. PLoS Negl Trop Dis. 2019;13(2):e0007042. doi: 10.1371/journal.pntd.0007042
   PubMed Web of Science ®Google Scholar
• Zhao G, Zhang Z, Ding Y, et al. A DNA vaccine encoding the full-length spike protein of beta variant (B.1.351) elicited broader cross-reactive immune responses against other SARS-CoV-2 variants. Vaccines (Basel). 2023;11(3):11. doi: 10.3390/vaccines11030513
   Web of Science ®Google Scholar
• Choi H, Kudchodkar SB, Ho M, et al. A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus. PLoS Negl Trop Dis. 2020;14(10):14. doi: 10.1371/journal.pntd.0008788
   Web of Science ®Google Scholar
• Muthumani K, Griffin BD, Agarwal S, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMenv DNA vaccine. NPJ Vaccin. 2016;1(1):1. doi: 10.1038/npjvaccines.2016.21
   Google Scholar
• Babuadze GG, Fausther-Bovendo H, de LaVega MA, et al. Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters. NPJ Vaccin. 2022;7(1). doi: 10.1038/s41541-022-00461-5
   Web of Science ®Google Scholar
• Muthumani K, Wise MC, Broderick KE, et al. HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo. PLoS One. 2013;8(12):e84234. doi: 10.1371/journal.pone.0084234
   PubMed Web of Science ®Google Scholar
• Jiang J, Ramos SJ, Bangalore P, et al. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses. Vaccine. 2019;37(29):3832–3839. doi: 10.1016/j.vaccine.2019.05.054
   PubMed Web of Science ®Google Scholar
• Patel A, Reuschel EL, Kraynyak KA, et al. Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines. J Infect Dis. 2019;219(4):544–555. doi: 10.1093/infdis/jiy537
   PubMed Web of Science ®Google Scholar
• Cashman KA, Wilkinson ER, Shaia CI, et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum Vaccin Immunother. 2017;13(12):2902–2911. doi: 10.1080/21645515.2017.1356500
   PubMed Web of Science ®Google Scholar
• Hirao LA, Draghia-Akli R, Prigge JT, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis. 2011;203(1):95–102. doi: 10.1093/infdis/jiq017
   PubMed Web of Science ®Google Scholar
• Jiang J, Banglore P, Cashman KA, et al. Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Hum Vaccin Immunother. 2019;15(9):2066–2074. doi: 10.1080/21645515.2019.1616499
   PubMed Web of Science ®Google Scholar
• Xie P, Li Y, Li Y, et al. Immune effect of a Newcastle disease virus DNA vaccine with IL-12 as a molecular adjuvant delivered by electroporation. Arch Virol. 2020;165(9):1959–1968. doi: 10.1007/s00705-020-04669-5
   PubMed Web of Science ®Google Scholar
• Sheng Z, Chen H, Feng K, et al. Electroporation-mediated Immunization of a candidate DNA vaccine expressing Dengue virus serotype 4 prM-E antigen confers long-term protection in mice. Virol Sin. 2019;34(1):88–96. doi: 10.1007/s12250-019-00090-8
   PubMed Web of Science ®Google Scholar
• Sheng Z, Gao N, Cui X, et al. Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. Vaccine. 2016;34(47):5751–5757. doi: 10.1016/j.vaccine.2016.10.001
   PubMed Web of Science ®Google Scholar
• Chen H, Zheng X, Wang R, et al. Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection. Clin Immunol. 2016;171:41–49. doi: 10.1016/j.clim.2016.08.021
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Keelapang P, et al. Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines. PLoS One. 2014;9(6):e92643. doi: 10.1371/journal.pone.0092643
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Tharakhet K, et al. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS One. 2021;16(3):e0248007. doi: 10.1371/journal.pone.0248007
   PubMed Web of Science ®Google Scholar
• Mucker EM, Golden JW, Hammerbeck CD, et al. A nucleic acid-based orthopoxvirus vaccine targeting the vaccinia virus L1, A27, B5, and A33 proteins protects rabbits against lethal rabbitpox virus aerosol challenge. J Virol. 2022;96(3). doi: 10.1128/JVI.01504-21
   PubMed Web of Science ®Google Scholar
• De PD, Van GE, Chen A, et al. A therapeutic hepatitis b virus DNA vaccine induces specific immune responses in mice and non-human primates. Vaccines (Basel). 2021;9(9):969. doi: 10.3390/vaccines9090969
   PubMed Web of Science ®Google Scholar
• Cashman K, Broderick K, Wilkinson E, et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a Guinea pig disease model when delivered by Dermal Electroporation. Vaccines (Basel). 2013;1(3):262–277. doi: 10.3390/vaccines1030262
   PubMedGoogle Scholar
• Martins M, Do Nascimento GM, Conforti A, et al. A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. Arch Virol. 2023;168(4):168. doi: 10.1007/s00705-023-05746-1
   PubMed Web of Science ®Google Scholar
• Hawman DW, Ahlén G, Appelberg KS, et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model. Nat Microbiol. 2020;6(2):187–195. doi: 10.1038/s41564-020-00815-6
   PubMed Web of Science ®Google Scholar
• Ivory C, Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther. 2004;2(1):17. doi: 10.1186/1479-0556-2-17
   PubMedGoogle Scholar
• Jain S, Afley P, Dohre SK, et al. Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice. Vaccine. 2014;32(35):4537–4542. doi: 10.1016/j.vaccine.2014.06.012
   PubMed Web of Science ®Google Scholar
• Cao Y, Hayashi CTH, Zavala F, et al. Effective functional immunogenicity of a DNA vaccine combination delivered via in vivo electroporation targeting malaria infection and transmission. Vaccines (Basel). 2022;10(7):10. doi: 10.3390/vaccines10071134
   Web of Science ®Google Scholar
• Kim NY, Chang DS, Kim Y, et al. Enhanced immune response to DNA vaccine encoding Bacillus anthracis PA-D4 protects mice against anthrax spore challenge. PLoS One. 2015;10(10):10. doi: 10.1371/journal.pone.0139671
   Web of Science ®Google Scholar
• Ferraro B, Talbott KT, Balakrishnan A, et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun. 2013;81(10):3709–3720. doi: 10.1128/IAI.00180-13
   PubMed Web of Science ®Google Scholar
• Vijayachari P, Vedhagiri K, Mallilankaraman K, et al. Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45. Hum Vaccin Immunother. 2015;11(8):1945–1953. doi: 10.1080/21645515.2015.1047117
   PubMed Web of Science ®Google Scholar
• Liang Y, Cui L, Xiao L, et al. Immunotherapeutic effects of different doses of Mycobacterium tuberculosis ag85a/b DNA vaccine delivered by Electroporation. Front Immunol. 2022;13: doi: 10.3389/fimmu.2022.876579
   Web of Science ®Google Scholar
• Datta D, Bansal GP, Gerloff DL, et al. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine. 2017;35(2):264–272. doi: 10.1016/j.vaccine.2016.11.072
   PubMed Web of Science ®Google Scholar
• Datta D, Bansal GP, Kumar R, et al. Evaluation of the impact of codon optimization and N-linked glycosylation on functional immunogenicity of Pfs25 DNA vaccines delivered by in vivo electroporation in preclinical studies in mice. Clin Vaccin Immunol. 2015;22(9):1013–1019. doi: 10.1128/CVI.00185-15
   PubMedGoogle Scholar
• Kumar R, Nyakundi R, Kariuki T, et al. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine. 2013;31(31):3140–3147. doi: 10.1016/j.vaccine.2013.05.006
   PubMed Web of Science ®Google Scholar
• Donate A, Heller R. Assessment of delivery parameters with the multi-electrode array for development of a DNA vaccine against Bacillus anthracis. Bioelectrochemistry. 2013;94:1–6. doi: 10.1016/j.bioelechem.2013.04.004
   PubMed Web of Science ®Google Scholar
• Broderick KE, Humeau LM. Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines. 2015;14(2):195–204. doi: 10.1586/14760584.2015.990890
   PubMed Web of Science ®Google Scholar